Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC),
and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality …

Background: The BRAF V600E mutation, the most frequent genetic alteration in papillary
thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor. The aim of this …

Thyroid carcinoma consists a group of phenotypically heterogeneous cancers. Recent
advances in biological technologies have been advancing the delineation of genetic …

The Kirsten rat sarcoma viral oncogene homolog (RAS)/v-raf-1 murine leukemia viral
oncogene homolog 1 (RAF)/mitogen-activated protein kinase 1 (MAPK) signaling cascade is …

Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …

Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …